This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cooke, J. P Search for Related Content PubMed PubMed Citation Articles by Cooke, J. P Social Bookmarking                         What's this?

ADMA: its role in vascular disease

Stanford University School of Medicine, Stanford, CA, USA, john.cooke{at}stanford.edu

Endothelium-derived nitric oxide (NO) is the most potent endogenous vasodilator and, by virtue of its anti-inflammatory and anti-thrombotic effects, it is an endogenous anti-atherogenic agent. Accordingly, impairment of NO synthesis or bioactivity may increase the risk of vascular disease. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of the NO synthase pathway. Plasma levels of ADMA are increased in patients with vascular disease, or with risk factors for vascular disease. Preclinical and clinical studies indicate that ADMA may mediate the adverse effects of traditional risk factors on endothelial vasodilator function. By impairing endothelial function, ADMA may contribute to pulmonary or systemic hypertension, as well as to vascular disease. Several drugs known to treat cardiovascular disease also reduce plasma ADMA levels, such as angiotensin receptor antagonists, converting enzyme inhibitors, and insulin sensitizing agents. Plasma ADMA may be a common mediator of endothelial dysfunction induced by vascular risk factors. Insights into the mechanisms by which plasma ADMA is regulated may lead to new therapeutic knowledge.

Key Words: dimethylarginine • endothelium • nitric oxide

Vascular Medicine, Vol. 10, No. 2 suppl, S11-S17 (2005)
DOI: 10.1191/1358863x05vm598oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Aversa, R. Bruzziches, D. Francomano, M. Natali, and A. Lenzi Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? Therapeutic Advances in Urology, October 1, 2009; 1(4): 179 - 197. [Abstract] [PDF]

				B. Wojciak-Stothard, B. Torondel, L. Zhao, T. Renne, and J. M. Leiper Modulation of Rac1 Activity by ADMA/DDAH Regulates Pulmonary Endothelial Barrier Function Mol. Biol. Cell, January 1, 2009; 20(1): 33 - 42. [Abstract] [Full Text] [PDF]

				S. Nakata, M. Tsutsui, H. Shimokawa, O. Suda, T. Morishita, K. Shibata, Y. Yatera, K. Sabanai, A. Tanimoto, M. Nagasaki, et al. Spontaneous Myocardial Infarction in Mice Lacking All Nitric Oxide Synthase Isoforms Circulation, April 29, 2008; 117(17): 2211 - 2223. [Abstract] [Full Text] [PDF]

				L. Hong and W. Fast Inhibition of Human Dimethylarginine Dimethylaminohydrolase-1 by S-Nitroso-L-homocysteine and Hydrogen Peroxide: ANALYSIS, QUANTIFICATION, AND IMPLICATIONS FOR HYPERHOMOCYSTEINEMIA J. Biol. Chem., November 30, 2007; 282(48): 34684 - 34692. [Abstract] [Full Text] [PDF]

				D. Wang, P. S. Gill, T. Chabrashvili, M. L. Onozato, J. Raggio, M. Mendonca, K. Dennehy, M. Li, P. Modlinger, J. Leiper, et al. Isoform-Specific Regulation by NG,NG-Dimethylarginine Dimethylaminohydrolase of Rat Serum Asymmetric Dimethylarginine and Vascular Endothelium-Derived Relaxing Factor/NO Circ. Res., September 14, 2007; 101(6): 627 - 635. [Abstract] [Full Text] [PDF]

				A. O. Yildirim, P. Bulau, D. Zakrzewicz, K. E. Kitowska, N. Weissmann, F. Grimminger, R. E. Morty, and O. Eickelberg Increased Protein Arginine Methylation in Chronic Hypoxia: Role of Protein Arginine Methyltransferases Am. J. Respir. Cell Mol. Biol., October 1, 2006; 35(4): 436 - 443. [Abstract] [Full Text] [PDF]